My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 151

    1.

    Predicted biological activity of intravitreal VEGF Trap.

    Stewart MW, Rosenfeld PJ.

    Br J Ophthalmol. 2008 May;92(5):667-8. Epub 2008 Mar 20.PMID: 18356264 [PubMed - indexed for MEDLINE]Related articles

    2.

    Predicted biologic activity of intravitreal bevacizumab.

    Stewart MW.

    Retina. 2007 Nov-Dec;27(9):1196-200.PMID: 18046224 [PubMed - indexed for MEDLINE]Related articles

    3.

    Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X; Tübingen Bevacizumab Study Group, Grisanti S.

    Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1. Epub 2008 Aug 16.PMID: 18708261 [PubMed - indexed for MEDLINE]Related articles

    4.

    Pharmacokinetics of intravitreal ranibizumab (Lucentis).

    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ.

    Ophthalmology. 2007 Dec;114(12):2179-82.PMID: 18054637 [PubMed - indexed for MEDLINE]Related articles

    5.

    Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

    Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V.

    Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33.PMID: 15671306 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.

    Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA.

    Retina. 2007 Nov-Dec;27(9):1260-6.PMID: 18046235 [PubMed - indexed for MEDLINE]Related articles

    7.

    Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.

    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.

    Exp Eye Res. 2007 Oct;85(4):425-30. Epub 2007 Jun 13.PMID: 17714704 [PubMed - indexed for MEDLINE]Related articles

    8.

    Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.

    Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S.

    Retina. 2006 Oct;26(8):871-6.PMID: 17031285 [PubMed - indexed for MEDLINE]Related articles

    9.

    Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?

    la Cour M.

    Acta Ophthalmol Scand. 2007 Feb;85(1):2-4. No abstract available. PMID: 17244202 [PubMed - indexed for MEDLINE]Related articles

    10.

    Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function.

    Fraser HM, Wilson H, Rudge JS, Wiegand SJ.

    J Clin Endocrinol Metab. 2005 Feb;90(2):1114-22. Epub 2004 Nov 23.PMID: 15562010 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    [The results of wet AMD treatment by intravitreal injections--preliminary report]

    Okruszko A, Borucka AI, Ulińska M, Szaflik J.

    Klin Oczna. 2007;109(10-12):389-93. Polish. PMID: 18488380 [PubMed - indexed for MEDLINE]Related articles

    12.

    Neovascular age-related macular degeneration: potential therapies.

    Chappelow AV, Kaiser PK.

    Drugs. 2008;68(8):1029-36. Review.PMID: 18484796 [PubMed - indexed for MEDLINE]Related articles

    13.

    Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity.

    Konner J, Dupont J.

    Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5. Review.PMID: 15479484 [PubMed - indexed for MEDLINE]Related articles

    14.

    Pharmacokinetics of intravitreal bevacizumab (Avastin).

    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ.

    Ophthalmology. 2007 May;114(5):855-9.PMID: 17467524 [PubMed - indexed for MEDLINE]Related articles

    15.

    [Ranibizumab for treatment of exudative age-related macular degeneration--own experience]

    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.

    Klin Oczna. 2007;109(10-12):402-9. Polish. PMID: 18488382 [PubMed - indexed for MEDLINE]Related articles

    16.

    Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.

    Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P.

    Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1837-42. Epub 2007 Mar 9.PMID: 17347807 [PubMed - indexed for MEDLINE]Related articles

    17.

    Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

    Krohne TU, Eter N, Holz FG, Meyer CH.

    Am J Ophthalmol. 2008 Oct;146(4):508-12. Epub 2008 Jul 17.PMID: 18635152 [PubMed - indexed for MEDLINE]Related articles

    18.

    Persisent ocular hypertension following intravitreal ranibizumab.

    Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM.

    Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-8. Epub 2008 Apr 19.PMID: 18425523 [PubMed - indexed for MEDLINE]Related articles

    19.

    Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque.

    Fraser HM, Wilson H, Morris KD, Swanston I, Wiegand SJ.

    J Clin Endocrinol Metab. 2005 Oct;90(10):5811-8. Epub 2005 Jul 26.PMID: 16046580 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys.

    Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D.

    Mol Vis. 2008 Jan 10;14:37-49.PMID: 18246030 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity